Want to join the conversation?
$RL said, as a result of its Way Forward Plan, it expects to stabilize performance in FY18 and pivot to growth off of a smaller, more profitable base in FY19, with improving operating margins in both fiscal years. In FY20, the company is targeting market share growth and a mid-teens operating margin.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.